Research | Clinical Trials | Clinical Trial Details Page

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Conditions

Cocaine Dependence

Trial Phase

Phase 1

Trial Purpose and Description

Trial Purpose

We are testing to see if Galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to CBT using an innovative CBT computer program.


Participation Guidelines

Age:
18 Years - 50 Years
Gender:
Both

Eligibility Criteria


Inclusion Criteria:

- Males and females between ages of 18 and 50

- Enrolled in RNP methadone program and stable on methadone for at least 3 weeks

- Current cocaine abuse or dependence according to DSM-IV criteria

- No current medical problems and normal ECG

- If female, not currently pregnant or breast feeding and using reliable birth control

- Fluent in English and have at least a 6th grade reading level

- Can commit to 12 weeks of treatment and are willing to be randomized

Exclusion Criteria:

- Current major psychiatric illness including mood, psychotic or anxiety disorder

- History of major medical illnesses including asthma, chronic obstructive lung
disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm
disturbances

- Use of medications including beta blockers and NASAIDs

- Known allergy to Galantamine
Sponsor:
National Institute on Drug Abuse (NIDA)
Yale University
Dates:
December 2007
Last Updated:
September 26, 2011
Study HIC#:
0708002943

Clinicaltrials.gov ID: NCT00809835